Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection
Maria Jose Moran
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Dr. Moran and Dr. Fontanellas contributed equally to this article.
Search for more papers by this authorCorresponding Author
Antonio Fontanellas Ph.D.
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Dr. Fontanellas is a postdoctoral TMR Marie Curie Research Fellow
Laboratoire de Pathologie Moléculaire et Thérapie Génique. Université de Bordeaux II, 146 rue Léo Saignat, 33076 Bordeaux Cédex, France. Fax: 33-5-56-98-33-48===Search for more papers by this authorEric Brudieux
Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France
Search for more papers by this authorIsabelle Hombrados
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Search for more papers by this authorVictor de Ledinghen
Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France
Search for more papers by this authorPatrice Couzigou
Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France
Search for more papers by this authorHubert de Verneuil
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Search for more papers by this authorRafael Enriquez De Salamanca
Servicio de Medicina Interna Hospital Universitario 12 de Octubre, Madrid, Spain
Search for more papers by this authorMaria Jose Moran
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Dr. Moran and Dr. Fontanellas contributed equally to this article.
Search for more papers by this authorCorresponding Author
Antonio Fontanellas Ph.D.
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Dr. Fontanellas is a postdoctoral TMR Marie Curie Research Fellow
Laboratoire de Pathologie Moléculaire et Thérapie Génique. Université de Bordeaux II, 146 rue Léo Saignat, 33076 Bordeaux Cédex, France. Fax: 33-5-56-98-33-48===Search for more papers by this authorEric Brudieux
Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France
Search for more papers by this authorIsabelle Hombrados
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Search for more papers by this authorVictor de Ledinghen
Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France
Search for more papers by this authorPatrice Couzigou
Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France
Search for more papers by this authorHubert de Verneuil
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France
Search for more papers by this authorRafael Enriquez De Salamanca
Servicio de Medicina Interna Hospital Universitario 12 de Octubre, Madrid, Spain
Search for more papers by this authorAbstract
Porphyria cutanea tarda (PCT) is caused by a decreased activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D). This deficiency causes overproduction, hepatic deposition, and increased excretion of uroporphyrin. Iron overload and hepatic viral infections are considered aggravating factors of the disease. Two forms of PCT have been described, as follows: a familial one with an inherited decrease of URO-D activity in all tissues and a sporadic one with a decreased activity of URO-D restricted to the liver. To assess whether the hepatic URO-D returns to normal during a remission of the disease, this activity was measured in liver biopsy samples in 24 sporadic PCT patients. The hepatic and urinary porphyrin concentrations were also measured. Viral status and histopathological findings were analyzed to assess their involvement in PCT. Six patients treated by phlebotomy to reduce hepatic iron and who were considered to be in clinical remission, characterized by a disappearance of cutaneous lesions, showed higher hepatic URO-D activities and lower hepatic porphyrin concentrations than did patients with overt PCT. The medians of these variables, however, did not achieve normal values. The hepatic URO-D activity showed a significant inverse relationship with both hepatic porphyrins and urinary uroporphyrin excretion. Hepatic URO-D activity was not reduced by hepatitis C virus (HCV) infection and liver damage. We conclude that the achievement of remission in PCT largely depends on the transient normalization of hepatic URO-D activity. A small increase in hepatic coproporphyrin in nonporphyric patients could reflect hepatic injury/iron/alcohol-induced oxidative stress oxidizing the accumulated heme precursors rather than a direct effect on hepatic URO-D enzyme.
REFERENCES
- 1 Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda. Decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976; 58: 1089–1097.MEDLINE
- 2 Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: CR Scriver, AL Beaudet, WS Sly, D Valle, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill, 1995; 2103–2159.
- 3 Quecedo L, Costa J, Enr&ıacute;quez de Salamanca R. Papel del virus de la hepatitis C en la hepatopat&ıacute;a de la porfiria cutánea tarda. Med Clin (Barc) 1996; 106: 321–324.MEDLINE
- 4 DeCastro M, Sanchez J, Herrera JF, Chaves A, Duran R, Garcia-Buey L, Garcia-Monzón C, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551–557.MEDLINE
- 5 Herrero C, Vicente A, Bruguera M, Ercilla MG, Barrera JM, Vidal J, Terés J, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341: 778–789.
- 6 Fargion S, Pipermo A, Cappellini MD, Sampietro M, Francanzani AL, Romano R, Caldarelli R, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322–1326.MEDLINE
- 7 Ferri C, Baicchi U, Civita LL, Greco F, Longombardo G, Mazzoni A, Careccia G, et al. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur J Clin Invest 1993; 23: 851–855.MEDLINE
- 8 Lacour JPH, Bodokh I, Castanet J, Bekri S, Ortonne JP. Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 1993; 128: 121–123.MEDLINE
- 9 Cribier B, Petiau P, Keller F, Schmitt C, Vetter D, Heid E, Grosshans E. Porphyria cutanea tarda and hepatitis C viral infection. Arch Dermatol 1995; 131: 801–804.MEDLINE
- 10 Lim HW, Harris HR, Fotiades J. Hepatitis C virus infection in patients with porphyria cutanea tarda evaluated in New York, NY. Arch Dermatol 1995; 131: 849.MEDLINE
- 11 Koester G, Feldman J, Bigler C. Hepatitis C in patients with porphyria cutanea tarda. J Am Acad Dermatol 1994; 31: 1054.MEDLINE
- 12 Siersema PD, ten Kate FJW, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992; 12: 56–61.MEDLINE
- 13 Murphy A, Dooley S, Hillary IB, Murphy GM. HCV infection in porphyria cutanea tarda. Lancet 1993; 341: 1534–1535.MEDLINE
- 14 Stölzel U, Köstler E, Koszka C, Stöffler-Meilicke M, Schuppan D, Somansundaram R, Doss MO, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21: 1500–1503.MEDLINE
- 15 Salmon P, Oakley A, Rademaker M, Duffill M. Hepatitis C virus infection and porphyria cutanea tarda in Australasia. Arch Dermatol 1996; 132: 91.MEDLINE
- 16 Verneuil H de, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea tarda. Two different diseases. Hum Genet 1978; 44: 145–151.MEDLINE
- 17 Felsher BF, Norris ME, Shih JC. Red-cell uroporphyrinogen decarboxylase activity in pophyria cutanea tarda. N Engl J Med 1982; 306: 166–169.MEDLINE
- 18
Elder GH,
Urquhart AJ,
de Salamanca RE,
Muñoz JJ,
Bonkovsky HL.
Immunoreactive uroporphyrinogen decarboxylase in the liver porphyria cutanea tarda.
Lancet
1985;
3: 229–233.
10.1016/S0140-6736(85)90287-9 Google Scholar
- 19 Siersema PD, Rademakers LHPM, Cleton MI, ten Kate FJW, de Brujin WC, Marx JJM, Wilson JHP. The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: the role of iron. J Hepatol 1995; 23: 259–267.MEDLINE
- 20 Knodell KG, Ishak KJ, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.MEDLINE
- 21 de Verneuil H, Grandchamp B, Nordmann Y. Some kinetic properties of human red cell uroporphyrinogen decarboxylase. Biochim Biophys Acta 1980; 611: 174–186.MEDLINE
- 22 Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilising the principle of protein dye-binding. Ann Biochem 1976; 72: 248–254.
- 23 Grandchamp B, Deybach JC, Greiler M, Verneuil H de, Nordmann Y. Studies of porphyrin synthesis in fibroblasts of patients with congenital erythropoietic porphyria and one patient with homozygous coproporphyria. Biochim Biophys Acta 1980; 629: 557–586.
- 24 Gajdos A, Gajdos-Torok M. Porphyrins et Porphyries. Paris, France: Masson and Cie. 1969; 212–220.
- 25 Sieg I, Doss MO, Kandels H, Schneider J. Effect of alcohol on δ -aminolevulinic acid dehydratase and porphyrin metabolism in man. Clin Chim Acta 1991; 202: 211–218.MEDLINE
- 26 Tsutsumi M, Takada A, Wang JS. Genetic polymorphisms of cytochrome P44502E1 related to the development of alcoholic liver disease. Gastroenterology 1994; 107: 1430–1435.MEDLINE
- 27 Alleman MA, Koster JF, Wilson JHP, Edixhoven-Bosdijk A, Slee RG, Kroos MJ, Von Ejik HG. The involvement of iron and lipid peroxidation in the pathogenesis of hexachlorobenzene induced porphyria. Biochem Pharmacol 1985; 34: 161–166.MEDLINE
- 28 Feldman ES, Bacon BR. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene induced porphyria with dietary carbonyl iron overload. Hepatology 1989; 9: 686–692.MEDLINE
- 29 Bonkovsky HL. Mechanism of iron potentiation of hepatic uroporphyria: studies in cultured chick embryo liver cells. Hepatology 1989; 10: 354–364.MEDLINE
- 30 Roberts AG, Whatley SD, Nicklin S, Worwood M, Pointon JJ, Stone C, El der GH. The frequency of haemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. 1 Hepatology 1997; 25: 159–161.MEDLINE
- 31 Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.MEDLINE
- 32 Santos M, Clevers HC, Marx JM. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. New Eng J Med 1997; 336: 1327–1328.MEDLINE
- 33 Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321–323.MEDLINE
- 34 Valls V, Enr&ıacute;quez de Salamanca R, Lapeña L, Campos I, Ena J, Guerra P, Rebollar JL. Hepatitis B serum markers in porphyria cutanea tarda. J Dermatol (Tokyo) 1986; 13: 24–29.
- 35 Enr&ıacute;quez de Salamanca R, Sanchez-Pérez J, D&ıacute;az-Mora F, Garc&ıacute;a-Escandón F, Pérez-Oteiza C, Verdejo J, Morán MJ, et al. Porphyria cutanea tarda associated with HIV infection: are those conditions pathogenetically or merely coincidental? AIDS 1990; 4: 296–297.
- 36 McAlister F, McClean K, Hamilton PG, Houston S. Human immunodeficiency virus infection and porphyria cutanea tarda: coexistence of risk factors or causative association? Clin Infect Dis 1995; 20: 348–351.MEDLINE
- 37 O'Connor WJ, Murphy GM, Darby C, Fogarty J, Mulcahy F, O'Moore R, Barnes L. Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch Dermatol 1996; 132: 1443–1447.MEDLINE
- 38 Poh-Fitzpatrick MB, Whitlock RT, Leftkowitch JH. Changes in protoporphyrin distribution dynamics during liver failure and recovery in a patient with protoporphyria and Epstein-Barr viral hepatitis. 5 Am J Med 1986; 80: 943–950.MEDLINE
- 39 Cribier B, Rey D, Uhl G, Le Coz C, Hirth C, Libbrecht E, Vetter D, et al. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. Arch Dermatol 1996; 132: 1448–1452.MEDLINE